MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy

Motofumi Yoshida, Yoshihiko Maehara, Keizo Sugimachi

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Fingerprint

Dive into the research topics of 'MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science